Developing therapeutic monoclonal antibodies at pandemic pace

Nature Biotechnology
Volume 38 Issue 5, May 2020
https://www.nature.com/nbt/volumes/38/issues/5

 

Comment | 21 April 2020
Developing therapeutic monoclonal antibodies at pandemic pace
The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.
Brian Kelley